» Articles » PMID: 12799559

Prevention of Mother-to-child Transmission of HIV in Africa: Successes and Challenges in Scaling-up a Nevirapine-based Program in Lusaka, Zambia

Overview
Journal AIDS
Date 2003 Jun 12
PMID 12799559
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Nearly half of perinatal HIV infection is preventable with nevirapine (NVP), which has transformed the ability to confront this transmission route in resource-limited settings.

Methods: A NVP-based perinatal HIV prevention program initiated in Lusaka, Zambia in November 2001.

Results: The first 12 months cost US$221 000 and enabled 178 district health employees to be trained in voluntary counseling and testing: 17 263 pregnant women were counseled for HIV, 12 438 (72%) were tested, and 2924 (24%) were found to be infected with HIV. NVP has been taken by 1654 (57%) mothers and 1157 (40%) babies. It is estimated that at least 190 infants have been spared HIV infection (11 per 1000 counseled women or 65 per 1000 identified HIV-infected women).

Conclusions: Prevention of mother-to-child HIV transmission is feasible and cost effective in resource-limited settings. In Lusaka, thousands of women have received voluntary counseling and testing and NVP therapy under the present scheme. Patient attrition and non-adherence represented a major source of program inefficiency, which requires to be systematically addressed.

Citing Articles

Factors Associated with HIV Testing Uptake in Cameroon: Data from the 2018 Cameroon Demographic and Health Survey.

Buh Nkum C, Nanfak A, Guenou E, Fri Kami R, Murhabazi Bashombwa A, Tchio-Nighie K HIV AIDS (Auckl). 2025; 17:9-17.

PMID: 39866749 PMC: 11766358. DOI: 10.2147/HIV.S496572.


Health technology assessment to support health benefits package design: a systematic review of economic evaluation evidence in Zambia.

Simangolwa W, Govender K, Mbonigaba J BMC Health Serv Res. 2024; 24(1):1426.

PMID: 39558344 PMC: 11572362. DOI: 10.1186/s12913-024-11914-z.


Costs and economies of scale in the accelerated program for prevention of mother-to-child transmission of HIV in Zimbabwe.

Ochoa-Moreno I, Bautista-Arredondo S, McCoy S, Buzdugan R, Mangenah C, Padian N PLoS One. 2020; 15(5):e0231527.

PMID: 32433715 PMC: 7239451. DOI: 10.1371/journal.pone.0231527.


Protocol for a prospective evaluation of postpartum engagement in HIV care among women living with HIV in South Africa.

Psaros C, Stanton A, Bedoya C, Mosery N, Evans S, Matthews L BMJ Open. 2020; 10(1):e035465.

PMID: 31924641 PMC: 6955573. DOI: 10.1136/bmjopen-2019-035465.


Access to prevention of mother-to-child transmission of HIV along HIV services cascade through integrated active case management in 15 operational districts in Cambodia.

Samreth S, Keo V, Tep R, Ke A, Ouk V, Ngauv B J Int AIDS Soc. 2019; 22(10):e25388.

PMID: 31631583 PMC: 6801228. DOI: 10.1002/jia2.25388.


References
1.
Guay L, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C . Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999; 354(9181):795-802. DOI: 10.1016/S0140-6736(99)80008-7. View

2.
Marseille E, Kahn J, Mmiro F, Guay L, Musoke P, Fowler M . Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet. 1999; 354(9181):803-9. DOI: 10.1016/S0140-6736(99)80009-9. View

3.
De Cock K, Fowler M, Mercier E, de Vincenzi I, Saba J, Hoff E . Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000; 283(9):1175-82. DOI: 10.1001/jama.283.9.1175. View

4.
Stringer J, Rouse D, Vermund S, Goldenberg R, Sinkala M, Stinnett A . Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2000; 24(4):369-77. DOI: 10.1097/00126334-200008010-00012. View

5.
Stringer E, Stringer J, Cliver S, Goldenberg R, Goepfert A . Evaluation of a new testing policy for human immunodeficiency virus to improve screening rates. Obstet Gynecol. 2002; 98(6):1104-8. DOI: 10.1016/s0029-7844(01)01631-3. View